Teenager’s Death Halts Amgen Pediatric Study of Sensipar

U.S. regulators halted Amgen Inc.’s pediatric clinical trials of the kidney drug Sensipar after a 14-year-old patient died.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.